Myocardial infarction risk among patients with fractures receiving bisphosphonates

Cory B. Pittman, Lisa A. Davis, Angelique L. Zeringue, Liron Caplan, Kent R. Wehmeier, Jeffrey F. Scherrer, Hong Xian, Francesca E. Cunningham, Jay R. McDonald, Alexis Arnold, Seth A. Eisen

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Objective: To determine if bisphosphonates are associated with reduced risk of acute myocardial infarction (AMI). Patients and Methods: A cohort of 14,256 veterans 65 years or older with femoral or vertebral fractures was selected from national administrative databases operated by the US Department of Veterans Affairs and was derived from encounters at Veterans Affairs facilities between October 1, 1998, and September 30, 2006. The time to first AMI was assessed in relationship to bisphosphonate exposure as determined by records from the Pharmacy Benefits Management Database. Time to event analysis was performed using multivariate Cox proportional hazards regression. An adjusted survival analysis curve and a Kaplan-Meier survival curve were analyzed. Results: After controlling for atherosclerotic cardiovascular disease risk factors and medications, bisphosphonate use was associated with an increased risk of incident AMI (hazard ratio, 1.38; 95% CI, 1.08-1.77; P.01). The timing of AMI correlated closely with the timing of bisphosphonate therapy initiation. Conclusion: Our observations in this study conflict with our hypothesis that bisphosphonates have antiatherogenic effects. These findings may alter the risk-benefit ratio of bisphosphonate use for treatment of osteoporosis, especially in elderly men. However, further analysis and confirmation of these findings by prospective clinical trials is required.

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalMayo Clinic Proceedings
Volume89
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Dive into the research topics of 'Myocardial infarction risk among patients with fractures receiving bisphosphonates'. Together they form a unique fingerprint.

Cite this